News

Cytoreduction and JAK Inhibitors Associated With Fewer Thrombotic Events in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis

09/30/2022

Gina Tomaine

Both conventional cytoreduction and JAK inhibitors were associated with fewer thrombotic events in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis, according to a recent study.

Both conventional cytoreduction...

09/30/2022

Oncology

News

FDA Approves Pemigatinib for Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

08/31/2022

Allison Casey

On August 26, 2022, the FDA approved pemigatinib for adult patients with relapsed or refractory myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement.

On August 26, 2022, the FDA...

08/31/2022

Oncology

News

Momelotinib Associated With Positive Survival Outcomes in Patients With Myelofibrosis: SIMPLIFY Trials

08/04/2022

Gina Tomaine

In the phase 3 SIMPLIFY trials, momelotinib demonstrated excellent OS and leukemia-free survival in patients with myelofibrosis, as well as activity against anemia, symptoms, and splenomegaly.

In the phase 3 SIMPLIFY trials,...

08/04/2022

Oncology

Conference Coverage

Momelotinib vs Danazol for Patients With Myelofibrosis: Findings From the MOMENTUM Trial

06/06/2022

Amber Denham

Findings from the phase 3 MOMENTUM trial demonstrate the superior efficacy of momelotinib vs danazol for symptomatic and anemic patients with myelofibrosis previously treated with a JAK inhibitor.

Findings from the phase 3...

06/06/2022

Oncology

News

Symptom Burden and Quality of Life With Cytoreductive Therapy in Essential Thrombocythemia and Polycythemia Vera

03/30/2022

John Otrompke

Findings from an analysis of the MPN-RC 111 trial help inform decisions regarding cytoreductive treatment timing and goals for patients with essential thrombocythemia and polycythemia vera.

Findings from an analysis of the...

03/30/2022

Oncology

News

Imetelstat Associated With High OS in Patients With R/R MF

03/21/2022

John Otrompke

Imetelstat was found to be associated with a significantly lower risk of death compared with “best available therapy” in patients with intermediate-to-high risk MF who had previously been treated with JAK inhibitors.

Imetelstat was found to be...

03/21/2022

Oncology

News

Researchers Further Characterize MPN First Identified in 1991, Offer Genetic Clues

03/08/2022

Researchers have identified 15 patients with a distinct MPN, which they propose naming “clonal megakaryocyte dysplasia.” This new disorder, according to the researchers, is distinct from pre-PMF.

Researchers have identified 15...

03/08/2022

Oncology

News

Antiplatelet, Anticoagulation Therapies Significantly Increase Bleeding Risk for MPNs

02/01/2022

A retrospective study found antiplatelet and anticoagulation therapies significantly increase the risk of bleeding in patients with MPNs without affecting mortality.

A retrospective study found...

02/01/2022

Oncology

News

Sotatercept is Safe, Effective for MPN-Associated MF Anemia

01/20/2022

Treatment with sotatercept was found to be safe and effective for anemic patients with MPN-associated MF, according to phase 2 data presented at the 2021 ASH Annual Meeting.

Treatment with sotatercept was...

01/20/2022

Oncology

News

Pulmonary Hypertension Suggest Worse Patient Outcomes in MPNs, CV Diseases

11/09/2021

Novel data presented at the 2021 ASH Annual Meeting investigated associations between MPNs and cardiovascular diseases. Further, pulmonary hypertension suggest worse patient outcomes with further investigation needed.

Novel data presented at the 2021...

11/09/2021

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology